Personalized Vaccine Support

About SpeciCare

SpeciCare is a private, early-stage company revolutionizing cancer care through its proprietary Live Tissue Science™ platform, which involves the collection, cryopreservation, and banking of live tumor tissue. This service model allows patients to retain ownership of their tissue, facilitating access to personalized medicine approaches like ex vivo drug testing, organoid creation, and clinical vaccine development outside of standard clinical pathways. Founded by surgical oncologist Dr. Ken Dixon, the company targets a significant gap in oncology by ensuring preserved tissue is available for future, evolving diagnostics and therapies, positioning itself as a patient-centric service in the precision medicine landscape. Its business appears to be service-based and likely pre-revenue or early revenue, focusing on building a biobank and partnering with researchers and clinicians.

Therapeutic Areas

Other Oncology (Broad) Drugs